EBS
Emergent Biosolutions Inc
6.60$
-3.7%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 45.7% | 51.6% | 52.6% | 45.4% | 27.8% | 29.5% | 41.5% | 42.9% | 38.2% | 37.3% | 43.1% | 50.2% | |
| 29.7% | 30.0% | 28.0% | 16.7% | 5.0% | 7.2% | 21.5% | 19.5% | 20.3% | 6.1% | 7.2% | 15.6% | |
| 29.7% | 30.0% | 28.0% | 16.7% | 5.0% | 7.2% | 21.5% | 19.5% | 20.3% | 6.1% | 7.2% | 15.6% | |
| 6.4% | 12.2% | 15.3% | 13.7% | 11.8% | 11.8% | 8.0% | 9.4% | 5.0% | 10.5% | 11.1% | 6.4% | |
| 6.9% | 7.4% | 7.6% | 13.3% | 9.2% | 9.6% | 10.6% | 11.6% | 11.1% | 18.0% | 22.4% | 26.0% | |
| 33.2% | 31.8% | 38.8% | 38.0% | 22.9% | 23.3% | 22.3% | 27.1% | 25.8% | 21.9% | 20.3% | 16.4% | |
| 4.4% | 5.3% | 4.2% | 4.6% | 11.6% | 11.5% | 9.3% | 7.6% | 6.9% | 12.0% | – | – | |
| 14.4% | 9.6% | 3.5% | 11.2% | 36.4% | 31.9% | 23.0% | 20.4% | 23.0% | 31.1% | 36.1% | 33.1% | |
| 41.5% | 36.8% | 38.5% | 14.8% | 54.7% | 53.2% | 49.8% | 45.5% | 56.2% | 64.4% | 65.3% | 60.4% | |
| 9.8% | 9.5% | 10.9% | 9.4% | 9.0% | 9.3% | 13.3% | 12.6% | 38.8% | 35.7% | 11.7% | 10.0% | |
| 4.3% | 4.1% | 2.1% | 4.0% | 0.5% | 0.7% | 1.6% | 1.3% | 30.4% | 22.7% | 0.2% | 0.0% | |
| 4.3% | 4.4% | 3.6% | 3.9% | 3.6% | 4.1% | 4.7% | 4.4% | 3.3% | 6.2% | 4.4% | 4.2% | |
| 26.6% | 24.2% | 25.6% | 1.3% | 35.2% | 34.3% | 29.2% | 27.4% | 14.2% | 24.5% | 47.8% | 43.4% | |
| 58.5% | 63.2% | 61.5% | 85.2% | 45.3% | 46.8% | 50.2% | 54.5% | 43.8% | 35.6% | 34.7% | 39.6% | |
| 30.5% | 33.6% | 26.2% | 31.5% | 16.5% | 18.1% | 25.2% | 32.1% | 23.3% | -1.2% | -15.3% | -12.1% | |
| 4.8% | 4.5% | 5.1% | 4.7% | 2.3% | 2.3% | 1.9% | 1.8% | 1.6% | 2.8% | 3.8% | 4.3% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.